Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

RxMine A simple blood test to choose the best treatment for each patient with depression.

Coordinator
Genetikaplus Ltd, Israel
Runs
1 June 2022 to 31 May 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190160513

What the project is doing

In the project's own words, from its summary on CORDIS.

Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to 170 billion to the EU. Despite numerous available drugs, 75% of patients do not receive adequate treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment. This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health care systems.

RxMine revolutionizes this process by combining innovative stem cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to 6,000 per patient per year.

Topics

Who is involved

OrganisationCityCountryRole
Genetikaplus LtdTel AvivIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI